View Financial HealthInnate Pharma 配当と自社株買い配当金 基準チェック /06Innate Pharma配当金を支払った記録がありません。主要情報n/a配当利回り-14.0%バイバック利回り総株主利回り-14.0%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesInnate Pharma SA to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026Apr 18Innate Pharma S.A., Annual General Meeting, May 21, 2026Apr 14Innate Pharma S.A. to Report Fiscal Year 2025 Results on Mar 26, 2026Dec 11+ 1 more updateInnate Pharma Announces FDA Clearance to Proceed with TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CCLNov 10Innate Pharma S.A. Appoints Yannis Morel as Chief Scientific OfficerSep 17Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) CongressJun 13Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis FungoidesMay 23Innate Pharma Highlights Anket® Abstracts for the Eha 2025 CongressMay 15Innate Pharma SA Highlights Preclinical Anti-Tumor Efficacy Data of its Antibody Drug Conjugate IPH4502 at AACR Annual MeetingApr 30Innate Pharma S.A. has completed a Follow-on Equity Offering in the amount of €14.999999 million.Apr 24Innate Pharma S.A. Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary SyndromeFeb 17Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid TumorsJan 27Innate Pharma S.A., Annual General Meeting, May 22, 2025Nov 21Innate Pharma S.A. to Report First Half, 2025 Results on Sep 17, 2025Nov 20+ 1 more updateInnate Pharma SA Announces Board ChangesOct 14+ 1 more updateAraris Biotech AG entered into an agreement to acquire ADC Transglutaminase Conjugation Technology Patents Portfolio from Innate Pharma S.A. (ENXTPA:IPH).Sep 26Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 TrialJun 18Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis FungoidesJun 05Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer PatientsApr 16Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug ConjugateApr 10Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s LymphomaMar 06Innate Pharma S.A. has filed a Follow-on Equity Offering in the amount of $75 million.Feb 07Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024Dec 18+ 1 more updateInnate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023Dec 11Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023Nov 03Innate Pharma S.A. to Report Q2, 2024 Results on Sep 12, 2024Oct 19+ 2 more updatesInnate Pharma S.A. Provides Update on Lacutamab Clinical ProgramOct 05Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023Sep 22Innate Pharma S.A. Announces Executive ChangesSep 15Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple MyelomaJul 12Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung CancerJun 27Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen CriteriaJun 17Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 CongressJun 12+ 1 more updateInnate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological MalignanciesJun 09Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AMLMay 27決済の安定と成長配当データの取得安定した配当: IDDAの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: IDDAの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Innate Pharma 配当利回り対市場IDDA 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (IDDA)n/a市場下位25% (DE)1.6%市場トップ25% (DE)4.5%業界平均 (Biotechs)2.3%アナリスト予想 (IDDA) (最長3年)n/a注目すべき配当: IDDAは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: IDDAは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: IDDAの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: IDDAが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/03/11 15:42終値2025/12/12 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Innate Pharma S.A. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。13 アナリスト機関Justin ZelinBTIGSuranjit MukherjeeBTIGYigal NochomovitzCitigroup Inc10 その他のアナリストを表示
Innate Pharma SA to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026Apr 18
Innate Pharma Announces FDA Clearance to Proceed with TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CCLNov 10
Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) CongressJun 13
Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis FungoidesMay 23
Innate Pharma SA Highlights Preclinical Anti-Tumor Efficacy Data of its Antibody Drug Conjugate IPH4502 at AACR Annual MeetingApr 30
Innate Pharma S.A. has completed a Follow-on Equity Offering in the amount of €14.999999 million.Apr 24
Innate Pharma S.A. Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary SyndromeFeb 17
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid TumorsJan 27
Araris Biotech AG entered into an agreement to acquire ADC Transglutaminase Conjugation Technology Patents Portfolio from Innate Pharma S.A. (ENXTPA:IPH).Sep 26
Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 TrialJun 18
Innate Pharma SA Presents Positive Results from TELLOMAK Phase 2 Study with Lacutamab in Mycosis FungoidesJun 05
Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer PatientsApr 16
Innate Pharma S.A. Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug ConjugateApr 10
Innate Pharma S.A. Announces First Patient Dosed in Phase 1/2 Study of IPH6501 in Relapsed /Refractory B-Cell Non-Hodgkin’s LymphomaMar 06
Innate Pharma Announces Resignation of Mondher Mahjoubi as Chief Executive Officer, Effective as of January 2024Dec 18+ 1 more update
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023Dec 11
Innate Pharma S.A. Announces New Clinical Data for Lacutamab and SAR443579/ IPH6101 at ASH 2023Nov 03
Innate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023Sep 22
Innate Pharma SA Announces First Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple MyelomaJul 12
Innate Pharma S.A. Announces First Patient Dosed in Matisse Trial of IPH5201 in Early Stage Lung CancerJun 27
Innate Pharma Sa Highlights Increased Lacutamab Clinical Activity from Interim Results of Phase 2 Tellomak Study with Updated Olsen CriteriaJun 17
Innate Pharma S.A. Highlights Proprietary Tetra-Specific Anket Nk Cell Engager Iph6501 At the Eha 2023 CongressJun 12+ 1 more update
Innate Pharma S.A. Announces SAR’579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological MalignanciesJun 09
Innate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AMLMay 27